Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Biogen Inc.

BIIBNASDAQ
Healthcare
Drug Manufacturers - General
$192.08
$0.00(0.00%)
U.S. Market opens in 1h 31m

Biogen Inc. (BIIB) Stock Overview

Explore Biogen Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap28.2B
P/E Ratio21.71
EPS (TTM)$8.79
ROE0.07%
Fundamental Analysis

AI Price Forecasts

1 Month$200.62
3 Months$225.51
1 Year Target$114.68

BIIB Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Biogen Inc. (BIIB) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 57.91, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $114.68.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 21.71 and a market capitalization of 28.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-0.03%
5-Day Change
-2.16%
1-Month Change
16.11%
3-Month Change
14.18%
6-Month Change
38.16%
Year-to-Date (YTD) Change
7.99%
1-Year Change
40.09%
3-Year Change
-29.38%
5-Year Change
-32.53%
All-Time (Max) Change
6044.96%

Contact Information

617 679 2000
225 Binney Street, Cambridge, MA, 02142

Company Facts

76,050 Employees
IPO DateSep 17, 1991
CountryUS
Actively Trading

Frequently Asked Questions